Research Group Genetics, Reproduction and Development, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Jette, Belgium.
Department of Biochemistry, Military Hospital 175, 786 Nguyen Kiem Street, Ho Chi Minh City 71409, Vietnam.
Cells. 2024 Aug 21;13(16):1395. doi: 10.3390/cells13161395.
Human pluripotent stem cells (hPSCs) are pivotal in regenerative medicine, yet their in vitro expansion often leads to genetic abnormalities, raising concerns about their safety in clinical applications. This study analyzed ten human embryonic stem cell lines across multiple passages to elucidate the dynamics of chromosomal abnormalities and single-nucleotide variants (SNVs) in 380 cancer-related genes. Prolonged in vitro culture resulted in 80% of the lines acquiring gains of chromosome 20q or 1q, both known for conferring an in vitro growth advantage. 70% of lines also acquired other copy number variants (CNVs) outside the recurrent set. Additionally, we detected 122 SNVs in 88 genes, with all lines acquiring at least one de novo SNV during culture. Our findings showed higher loads of both CNVs and SNVs at later passages, which were due to the cumulative acquisition of mutations over a longer time in culture, and not to an increased rate of mutagenesis over time. Importantly, we observed that SNVs and rare CNVs followed the acquisition of chromosomal gains in 1q and 20q, while most of the low-passage and genetically balanced samples were devoid of cancer-associated mutations. This suggests that recurrent chromosomal abnormalities are potential drivers for the acquisition of other mutations.
人多能干细胞(hPSCs)在再生医学中具有重要作用,但它们在体外的扩增往往会导致遗传异常,这引起了人们对其在临床应用中的安全性的担忧。本研究分析了跨越多个传代的十个人胚胎干细胞系,以阐明 380 个与癌症相关基因中的染色体异常和单核苷酸变异(SNVs)的动态。长时间的体外培养导致 80%的细胞系获得了染色体 20q 或 1q 的增益,这两种染色体都已知能赋予体外生长优势。70%的细胞系还获得了其他非重现性的拷贝数变异(CNVs)。此外,我们在 88 个基因中检测到了 122 个 SNVs,所有细胞系在培养过程中都获得了至少一个新的 SNV。我们的研究结果表明,随着传代的增加,CNVs 和 SNVs 的负荷都更高,这是由于在更长的时间内培养过程中积累了更多的突变,而不是随着时间的推移突变率增加。重要的是,我们观察到 SNVs 和罕见的 CNVs 是在 1q 和 20q 获得染色体增益之后出现的,而大多数低传代和遗传平衡的样本中没有癌症相关的突变。这表明反复出现的染色体异常可能是获得其他突变的潜在驱动因素。